| Item Type | Name |
|
Concept
|
Tumor Microenvironment
|
|
Academic Article
|
Immune suppression in the tumor microenvironment.
|
|
Academic Article
|
Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
|
|
Academic Article
|
Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment.
|
|
Academic Article
|
Immune resistance orchestrated by the tumor microenvironment.
|
|
Academic Article
|
The immune score as a new possible approach for the classification of cancer.
|
|
Academic Article
|
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
|
|
Academic Article
|
Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1.
|
|
Academic Article
|
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment.
|
|
Academic Article
|
Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer.
|
|
Academic Article
|
Cancer classification using the Immunoscore: a worldwide task force.
|
|
Academic Article
|
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment.
|
|
Academic Article
|
Targeting the tumor microenvironment with interferon-ß bridges innate and adaptive immune responses.
|
|
Academic Article
|
Therapeutic activity of high-dose intratumoral IFN-ß requires direct effect on the tumor vasculature.
|
|
Academic Article
|
New perspectives on type I IFNs in cancer.
|
|
Academic Article
|
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
|
|
Academic Article
|
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
|
|
Academic Article
|
Innate and adaptive immune cells in the tumor microenvironment.
|
|
Academic Article
|
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.
|
|
Academic Article
|
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.
|
|
Academic Article
|
The STING pathway and the T cell-inflamed tumor microenvironment.
|
|
Academic Article
|
Melanoma-intrinsic ß-catenin signalling prevents anti-tumour immunity.
|
|
Academic Article
|
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
|
|
Academic Article
|
Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
|
|
Academic Article
|
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
|
|
Academic Article
|
Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy.
|
|
Academic Article
|
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
|
|
Academic Article
|
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.
|
|
Academic Article
|
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer.
|
|
Academic Article
|
The host STING pathway at the interface of cancer and immunity.
|
|
Academic Article
|
Lymphatic vessels regulate immune microenvironments in human and murine melanoma.
|
|
Academic Article
|
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
|
|
Academic Article
|
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.
|
|
Academic Article
|
The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.
|
|
Academic Article
|
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
|
|
Academic Article
|
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
|
|
Academic Article
|
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
|
|
Academic Article
|
Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.
|
|
Academic Article
|
Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
|
|
Academic Article
|
WNT/ß-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
|
|
Academic Article
|
Brain Tumor Microenvironment and Host State: Implications for Immunotherapy.
|
|
Academic Article
|
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy).
|
|
Academic Article
|
Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion.
|
|
Academic Article
|
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy).
|
|
Academic Article
|
Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma.
|
|
Academic Article
|
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma.
|
|
Academic Article
|
Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration.
|
|
Academic Article
|
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
|